Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma

Fourniols, Thibaut; Randolph, Luc; Staub, Aurélie; Vanvarenberg, Kévin; Leprince, Julian; Préat, Véronique; Rieux, Anne des; Danhier, Fabienne

doi:10.1016/j.jconrel.2015.05.272

Cited by 95 publications

(64 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo, the anti-tumor efficacy of TMZ-hydrogel was evaluated on xenograft U87 tumor-bearing nude mice. The tumor weight of mice treated with the photopolymerized TMZ hydrogel decreased compared with all control groups and higher apoptosis was observed located at the center of the tumor (19). No data on overall survival of animals were reported.…”

Section: Polymeric Depotsmentioning

confidence: 96%

“…Overall, the therapeutic efficacy of treatment with carmustine wafers in HGG patients is limited or null. A polyethylene glycol dimethacrylate (PEG-DMA) injectable hydrogel that photopolymerizes in situ and may thus fit the borders of the resected zone thus providing sustained, local drug delivery has been investigated in order to improve local delivery of TMZ ( Figure 3A) (19). The hydrogel photopolymerized rapidly and presented a viscous modulus (approximately 10 kPa).…”

Section: Polymeric Depotsmentioning

confidence: 99%

See 1 more Smart Citation

Advances in drug delivery to high grade gliomas

Fròsina

2016

Brain Pathology

View full text Add to dashboard Cite

If cancer is hard to be treated, brain cancer is even more, caused by the inability of many effective drugs given systemically to cross the blood brain and blood tumor barriers and reach adequate concentrations at the tumor sites. Effective delivery of drugs to brain cancer tissues is thus a necessary, albeit not sufficient, condition to effectively target the disease. In order to analyze the current status of research on drug delivery to high grade gliomas (HGG-WHO grades III and IV), the most frequent and aggressive brain cancers, a literature search was conducted in PubMed using the terms: "drug delivery and brain tumor" over the publication year 2015. Currently explored drug delivery techniques for HGG include the convection and permeabilization-enhanced deliveries, drug-releasing depots and Ommaya reservoirs. The efficacy/safety ratio widely varies among these techniques and the success of current efforts to increase this ratio widely varies as well.

show abstract

Section: Polymeric Depotsmentioning

confidence: 96%

Section: Polymeric Depotsmentioning

confidence: 99%

Advances in drug delivery to high grade gliomas

Fròsina

2016

Brain Pathology

View full text Add to dashboard Cite

show abstract

“…They can be injected intratumorally or placed in the resection cavity after craniotomy. For example, an injectable PEG-dimethacrylate (PEG-DMA) hydrogel, which can be photopolymerized in situ, provided sustained release of temozolomide [69]. Some hydrogels have incorporated drug-loaded nanocarriers, including lipid nanocapsules loaded with lauroyl-gemcitabine [68], PLGA-PEG loaded with paclitaxel [70], and PLGA microspheres encapsulating camtothecin or vincristine [71].…”

Section: Other Local Drug Delivery Strategiesmentioning

confidence: 99%

Nanomaterials for convection-enhanced delivery of agents to treat brain tumors

Seo

Saltzman

2017

Current Opinion in Biomedical Engineering

View full text Add to dashboard Cite

Nanomaterials represent a promising and versatile platform for the delivery of therapeutics to the brain. Treatment of brain tumors has been a long-standing challenge in the field of neuro-oncology. The current standard of care – a multimodal approach of surgery, radiation and chemotherapy – yields only a modest therapeutic benefit for patients with malignant gliomas. A major obstacle for treatment is the failure to achieve sufficient delivery of therapeutics at the tumor site. Recent advances in local drug delivery techniques, along with the development of highly effective brain-penetrating nanocarriers, have significantly improved treatment and imaging of brain tumors in preclinical studies. The major advantage of this combined strategy is the ability to optimize local therapy, by maintaining an effective and sustained concentration of therapeutics in the brain with minimal systemic toxicity. This review highlights some of the latest developments, significant advancements and current challenges in local delivery of nanomaterials for the treatment of brain tumors.

show abstract

“…Glioblastoma is the most damaging brain tumours of the central nervous system. These malignant (cancerous) brain tumours exhibit a high proliferation rate, changeability in tumour histopathology and diffusely penetrate adjacent brain tissue along network of blood vessels (Bernardi et al, 2009;Fourniols et al, 2015). Glioblastoma is mainly dangerous cancers in humans with an average survival after maximal therapy of <2 years after initial identifications of cancer (Chaichana et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…TMZ is an alkylating agent; these alkylating species inhibits DNA replication by delivering a methyl group to purine bases of DNA (N7-guanine, O6-guanine and N3-adenine) (Zhang, Stevens, & Bradshaw, 2012). TMZ drug is a fast degradable and short plasma half-life of 1.8 hr, encapsulation of TMZ drug into nanomaterials can be advantageous to attain the controlled, stable and sustained release of the TMZ drug for inhibition of tumour cells growth, several nanomaterials have been studied, which were listed in the Table 1 (Akbar et al, 2009;Fang et al, 2015;Fourniols et al, 2015;Huang, Lin, Wen, Gu, & Zhao, 2016;Irani, Sadeghi, & Haririan, 2018;Irani et al, 2017aIrani et al, , 2017bKumari, Ahsan, Kumar, Kondapi, & Rao, 2017; Lanz-Landázuri, Portilla-Arias, Martínez de Ilarduya, García-Alvarez, & Holler, 2014;Ni, Fan, Wang, Qi, & Li, 2014;Ramachandran et al, 2017;Scott et al, 2011;Tavakoli et al, 2017;Xu, Shen, et al, 2016;Zhang & Gao, 2007;Zheng, Wang, Liu, Xie, & Deng, 2018). In addition, the advantage of local delivery of TMZ drug as compared with oral administration has been shown in rodent glioblastoma models (Ni et al, 2014;Brem et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Reduced graphene oxide‐based electrochemically stimulated method for temozolomide delivery

et al. 2018

View full text Add to dashboard Cite

The controlled release of drug molecules to a specific brain tumour's tissue has been recognized as one of the most demanding researches for treatment of brain cancer, because it helps to avoid the side effects from systemic drug delivery techniques. In the present work, described an electrochemically controlled drug delivery performed with a reduced graphene oxide (rGO)‐drug composite. The rGO was loaded with a temozolomide (TMZ) molecule (rGO‐TMZ) exhibits electrochemical oxidation and reduction peak in 0.1 M phosphate buffer solution (pH 7.4). In response to be electrochemical potential, the rGO‐TMZ composite releases TMZ drug, and TMZ drug dosage that can be adjusted by altering the electrochemical potential with time. Upon application of an electrochemical potential pulse (0.8 V) for 20 min duration, up to 83% of TMZ was released into citrate buffer solution at pH 5.0. In vitro, cell culture experiments demonstrate that the released TMZ drug retains its bioactivity. The electrochemically controlled rGO‐TMZ composite drug delivery platform makes it an exciting candidate for on‐demand drug delivery for effective treatment of brain cancer.

show abstract

Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma

Cited by 95 publications

References 33 publications

Advances in drug delivery to high grade gliomas

Advances in drug delivery to high grade gliomas

Nanomaterials for convection-enhanced delivery of agents to treat brain tumors

Reduced graphene oxide‐based electrochemically stimulated method for temozolomide delivery

Contact Info

Product

Resources

About